Authors: Spinelli FR, Conti F, Gadina M PMID: 32385052 DOI: 10.1126/sciimmunol.abc5367 Abstract JAK kinase inhibitors are being investigated as a way of managing cytokine storm in severe COVID-19 patients. Keywords: SARS-CoV-2, JAK inhibitors, COVID-19 Source: https://pubmed.ncbi.nlm.nih.gov/32385052/ Archive: https://archive.ph/Jwcrd

Authors: Patterson BK, seethamraju H, Dhody K, Corley MJ, Pang AP PMID: 32511656 PMCID: PMC7277012 DOI: 10.1101/2020.05.02.20084673 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is now pandemic with nearly three million cases reported to date. Although the majority of COVID-19 patients experience only mild or moderate [...]

Authors: Dayer MR doi: 10.20944/preprints202005.0020.v1 Abstract The disease of COVID-19 comprises the most serious against human health worldwide with a high rate of virulence and mortality. The disease is caused by the 2019-nCoV virus from the beta coronavirus family. The virus makes use of its surface glycoprotein named S protein or spike to enter the [...]

Authors: Patel AN, Desai SS, Grainger DW, Mehra MR Abstract Importance: There is no established anti-viral therapy for treating COVID-19 illness. Objective: To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19 outcomes. Design: An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with [...]

Authors: Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG PMID: 32356926 PMCID: PMC7267340 DOI: 10.1002/ddr.21679 Abstract In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 [...]

Authors: Villar J, Confalonieri M, Pastores SM, Meduri GU PMID: 32426753 PMCID: PMC7188431 DOI: 10.1097/CCE.0000000000000111 Abstract In December 2019, pneumonia associated with the novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. On March 14, 2020, the World Health Organization (WHO) declared the coronavirus outbreak a pandemic with confirmed cases in 127 countries. This unprecedented [...]

The current COVID-19 pandemic is one of the most devastating events in recent history. The virus causes relatively minor damage to young, healthy populations, imposing life-threatening danger to the elderly and people with diseases of chronic inflammation. Therefore, if we could reduce the risk for vulnerable populations, it would make the COVID-19 pandemic more similar to other typical outbreaks.

Authors: Leisman DE, Deutschman CS, Legrand M PMID: 32347323 PMCID: PMC7186535 DOI: 10.1007/s00134-020-06059-6 Abstract Current management guidelines for COVID-19 reflect the assumption that critically ill patients infected with SARS-CoV-2 develop acute respiratory distress syndrome (ARDS). However, emerging data and clinical reports increasingly suggest an alternative view that severe COVID-19 reflects a confluence of vascular dysfunction, [...]

Authors: Tay MZ, Poh CM, Renia L, MacAry PA PMID: 32346093 PMCID: PMC7187672 DOI: 10.1038/s41577-020-0311-8 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 [...]

Authors: Theoharides TC PMID: 32339387 PMCID: PMC7267424 DOI: 10.1002/biof.1633 Abstract The new coronavirus (severe acute pulmonary syndrome [SARS]‐CoV‐2) originated in China, where it spread rapidly, and has reached pandemic proportions because of its high rate of infectivity as well as high morbidity and mortality, associated with COVID‐19. This coronavirus infects by first binding to the [...]